Fate Therap(FATE.US)

Last Updated 19:00:00 ET
longbridge loading

Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation

Simplywall·
US
FATE
-2.65%
US
SBIO
+3.75%
US
IBB
+2.27%
Simplywall·
US
FATE
-2.65%
US
SBIO
+3.75%
US
IBB
+2.27%

Pre-market hot trades in US stocks: Fate Therap pre-market down 7.73%; MACOM Technology Solutions Holdings pre-market up 7.44%

Price Alert·
US
FATE
-2.65%
US
MTSI
+4.66%
Price Alert·
US
FATE
-2.65%
US
MTSI
+4.66%

Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell Therapies

Tip Ranks·
US
FATE
-2.65%
US
SBIO
+3.75%
US
IBBQ
+2.43%
Tip Ranks·
US
FATE
-2.65%
US
SBIO
+3.75%
US
IBBQ
+2.43%

Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks

Tip Ranks·
US
FATE
-2.65%
US
XBI
+3.88%
US
FBT
+2.14%
Tip Ranks·
US
FATE
-2.65%
US
XBI
+3.88%
US
FBT
+2.14%

Fate Therap | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.299 M

Earnings Watch·
US
FATE
-2.65%
Earnings Watch·
US
FATE
-2.65%

U.S. stock market midday update: Fate Therapeutics rises 23.61%, driven by dual benefits from FDA projects and analyst ratings boosting stock price

Price Alert·
US
FATE
-2.65%
Price Alert·
US
FATE
-2.65%

Pre-market hot trades in US stocks: Fate Therap up 7.78% in pre-market; Maison Solutions down 7.53% in pre-market

Price Alert·
US
FATE
-2.65%
US
MSS
-3.03%
Price Alert·
US
FATE
-2.65%
US
MSS
-3.03%

U.S. stock night market fluctuations: Fate Therapeutics rose 7.22% in after-hours trading, analysts raised the target price and the CAR T therapy presentation boosted market confidence

Price Alert·
US
FATE
-2.65%
Price Alert·
US
FATE
-2.65%
© 2026 Longbridge｜Disclaimer